LEXICON PHARMACEUTICALS, INC. 10-Q

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds The following table provides information about our purchases of shares of our common stock during the three months ended March 31, 2021: 23 Period Total Number of Shares Purchased Average Price Paid Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Maximum Number of Shares that May Yet be Purchased Under the Plans or Programs (3) January 1-31, 2021 — $ — — — February 1-28, 2021 372,040 (1) $ 7.19 (2) — — March 1-31, 2021 — $ — — — (1) Represents shares retained by us in satisfaction of the tax withholding obligations of recipients of restricted stock units granted in February 2017, February 2018, February 2019 and February 2020 under our 2017 Equity Incentive Plan with respect to the vesting of such restricted stock units. (2) Represents the market price of our common stock on the date of vesting of such restricted stock units, calculated in accordance with the process for determination of fair market value under our 2017 Equity Incentive Plan. (3) In the future, we may grant additional equity securities under our 2017 Equity Incentive Plan for which the recipient's tax withholding obligations with respect to the grant or vesting of such securities may be satisfied by our retention of a portion of such securities. Further, for any such equity securities which are subject to vesting conditions, the number of equity securities which we may retain in satisfaction of the recipient's tax withholding obligations may be dependent on the continued employment of such recipient or other performance-based conditions. Accordingly, we cannot predict with any certainty either the total amount of equity securities or the approximate dollar value of such securities that we may purchase in future years. 24 Item 6. Exhibits Exhibit No. Description 3.1 — Second Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K dated April 29, 2021 and incorporated by reference herein). 10.1 — 2017 Non-Employee Directors’ Equity Incentive Plan , as amended (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated April 29, 2021 and incorporated by reference herein). *31.1 — Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *31.2 — Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *32.1 — Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS — XBRL Instance Document 101.SCH — XBRL Taxonomy Extension Schema Document 101.CAL — XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF — XBRL Taxonomy Extension Definition Linkbase Document 101.LAB — XBRL Taxonomy Extension Label Linkbase Document 101.PRE — XBRL Taxonomy Extension Presentation Linkbase Document _____________________ * Filed herewith. 25 Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lexicon Pharmaceuticals, Inc. Date: May 6, 2021 By: /s/ Lonnel Coats Lonnel Coats President and Chief Executive Officer Date: May 6, 2021 By: /s/ Jeffrey L. Wade Jeffrey L. Wade Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer 26